Halberd (Halberd) Change In Payables And Accrued Expense : $0.21 Mil (TTM As of Jul. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Halberd Change In Payables And Accrued Expense?

Halberd's Change In Payables And Accrued Expense for the quarter that ended in Jul. 2023 was $0.21 Mil. It means Halberd's Accounts Payable & Accrued Expense increased by $0.21 Mil from Jul. 2022 to Jul. 2023 .

Halberd's Change In Payables And Accrued Expense for the fiscal year that ended in Jul. 2023 was $0.21 Mil. It means Halberd's Accounts Payable & Accrued Expense increased by $0.21 Mil from Jul. 2022 to Jul. 2023 .

Halberd Change In Payables And Accrued Expense Historical Data

The historical data trend for Halberd's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Change In Payables And Accrued Expense Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

Change In Payables And Accrued Expense

0.07

0.21

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
Change In Payables And Accrued Expense	0.07	0.21	0.21

Halberd Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jul. 2023 was $0.21 Mil.

Halberd Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Halberd's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236